Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. R. Hurst, T. A. R. Seemungal, T. M. A. Wilkinson, W. R. Perera, R. J. Sapsford, J. A. Wedzicha (Royal Free Campus, United Kingdom). Plasma biomarker assay and the immuno-modulatory effect of erythromycin in COPD. Eur Respir J 2009; 34: Suppl. 53, 4461

Member's Comments

No comment yet.

Related content which might interest you: Plasma biomarkers and response to therapy at exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 39s Year: 2007 The effect of a novel anti-inflammatory agent (ODSH) on C-reactive protein in patients with an acute exacerbation of COPD Source: Annual Congress 2009 - Acute lung injury and biomarkers Year: 2009 Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Effects of erdosteine on serum biomarker concentrations at COPD exacerbation Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 Serum surfactant protein D (SP-D) is a lung derived biomarker for COPD that is responsive to treatment with oral corticosteroids Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 The effect of methylxanthine, corticosteroid, and N -acetylcystein on plasma oxidant/antioxidant levels in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 215s Year: 2001 Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Amoxicillin concentrations in sputum in relation to betalactamase activity in COPD patients Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017 Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Changes in the anti-inflammatory treatment of COPD Source: Annual Congress 2012 - PG9 Progress on the treatment of COPD Year: 2012 Anti-inflammatory activity of macrolides in peripheral blood mononuclear cells and the identification of potential biomarkers of azithromycin administration Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011 Serum Club cell16 levels as a biomarker in tobacco-smoke COPD and biomass-smoke COPD Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018 The inhibitory effect of ciprofloxacin on bacterial adhesiveness is enhanced by the SH-metabolite I of erdosteine (mucolytic drug) Source: Eur Respir J 2001; 18: Suppl. 33, 543s Year: 2001 Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020